|
| Index | - | P/E | - | EPS (ttm) | -1.81 | Insider Own | 9.50% | Shs Outstand | 29.25M | Perf Week | -21.83% |
| Market Cap | 429.39M | Forward P/E | - | EPS next Y | - | Insider Trans | 151.45% | Shs Float | 0.08M | Perf Month | - |
| Income | -43.70M | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 0.00% | Perf Quarter | - |
| Sales | - | P/S | - | EPS this Y | -18.20% | Inst Trans | - | Short Ratio | 0.00 | Perf Half Y | - |
| Book/sh | - | P/B | - | EPS next Y | - | ROA | - | Target Price | - | Perf Year | - |
| Cash/sh | 0.18 | P/C | 82.58 | EPS next 5Y | - | ROE | - | 52W Range | 17.62 - 24.39 | Perf YTD | -18.58% |
| Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -39.81% | Beta | - |
| Dividend % | - | Quick Ratio | 0.60 | Sales past 5Y | - | Gross Margin | - | 52W Low | -16.69% | ATR | 1.57 |
| Employees | 37 | Current Ratio | 0.60 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | - | Volatility | 9.55% - |
| Optionable | No | Debt/Eq | - | EPS Q/Q | - | Profit Margin | - | Rel Volume | 0.58 | Prev Close | 17.67 |
| Shortable | Yes | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 441.75K | Price | 14.68 |
| Recom | - | SMA20 | -20.40% | SMA50 | -20.40% | SMA200 | -20.40% | Volume | 261,771 | Change | -16.92% |
 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin, or OTOF, gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy, or BVP, by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was founded in 2013 and is based in Boston, Massachusetts. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite